Company intelligence / Profile preview

ImmunoPharma

Ownership: Private
Development stage: Phase 2

Overview

ImmunoPharma appears to focus on nutraceutical health products, including a patented immunomodulating mushroom extract (AndoSan) with clinical research showing potential co-treatment benefits in inflammatory diseases[2]. No clinical trial data per pharma standards is available.

Therapeutic areas: OtherImmunologyCardiovascular
Modalities: Natural product
Industry: Food & Nutrition

Drug pipeline

1 asset

IMPT-314

Phase 2/3

Indications: Large B-cell lymphoma, B-cell non-Hodgkin lymphoma

Beyond the preview

Go deeper on ImmunoPharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImmunoPharma.

Explore the full profile